{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T01:28:11Z","timestamp":1768699691975,"version":"3.49.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ejmech.2021.114049","type":"journal-article","created":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T22:31:02Z","timestamp":1639780262000},"page":"114049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics"],"prefix":"10.1016","volume":"229","author":[{"given":"Hao","family":"Cui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianqian","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6130-2385","authenticated-orcid":false,"given":"Hongmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyang","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8623-7655","authenticated-orcid":false,"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haizhi","family":"Bu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingxu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dexiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yadong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0701-343X","authenticated-orcid":false,"given":"Yong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ejmech.2021.114049_bib1","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncol."},{"issue":"11","key":"10.1016\/j.ejmech.2021.114049_bib2","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2011-10-387365","article-title":"Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma","volume":"119","author":"Santo","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ejmech.2021.114049_bib3","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1517\/13543784.2011.594437","article-title":"Romidepsin: a novel histone deacetylase inhibitor for cancer","volume":"20","author":"Bertino","year":"2011","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"6","key":"10.1016\/j.ejmech.2021.114049_bib4","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s40265-015-0388-8","article-title":"Panobinostat: first global approval","volume":"75","author":"Garnock-Jones","year":"2015","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.ejmech.2021.114049_bib5","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s00280-012-1847-5","article-title":"Phase I study of chidamide (CS055\/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas","volume":"69","author":"Dong","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.114049_bib6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejmech.2019.02.032","article-title":"Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors","volume":"168","author":"Chen","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"14","key":"10.1016\/j.ejmech.2021.114049_bib7","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.2165\/11315680-000000000-00000","article-title":"Histone deacetylase inhibitors: current status and overview of recent clinical trials","volume":"69","author":"Ma","year":"2009","journal-title":"Drugs"},{"issue":"24","key":"10.1016\/j.ejmech.2021.114049_bib8","doi-asserted-by":"crossref","first-page":"8546","DOI":"10.1021\/jm100665z","article-title":"Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity","volume":"53","author":"Mahboobi","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2021.114049_bib9","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3390\/cancers12071869","article-title":"New insights into diffuse large B-cell lymphoma pathobiology","volume":"12","author":"Solimando","year":"2020","journal-title":"Cancers"},{"issue":"21","key":"10.1016\/j.ejmech.2021.114049_bib10","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2017-11-764332","article-title":"Genetics of diffuse large B-cell lymphoma","volume":"131","author":"Pasqualucci","year":"2018","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.ejmech.2021.114049_bib11","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1182\/blood-2016-03-705814","article-title":"An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL","volume":"128","author":"Mai","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ejmech.2021.114049_bib12","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.ejmech.2021.114049_bib13","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S1470-2045(18)30685-5","volume":"19","author":"Robak","year":"2018","journal-title":"Lancet Oncol."},{"issue":"28","key":"10.1016\/j.ejmech.2021.114049_bib14","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1200\/JCO.19.01048","article-title":"Above what age should ibrutinib not Be given with R-CHOP to patients with non-GBC DLBCL?","volume":"37","author":"Skelin","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ejmech.2021.114049_bib15","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/S2352-3026(20)30031-4","article-title":"Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis","volume":"7","author":"Linschoten","year":"2020","journal-title":"The Lancet Haematology"},{"issue":"10","key":"10.1016\/j.ejmech.2021.114049_bib16","doi-asserted-by":"crossref","first-page":"994","DOI":"10.7150\/ijms.8522","article-title":"Expression of histone deacetylases in diffuse large B-cell lymphoma and its clinical significance","volume":"11","author":"Lee","year":"2014","journal-title":"Int. J. Med. Sci."},{"issue":"7","key":"10.1016\/j.ejmech.2021.114049_bib17","doi-asserted-by":"crossref","first-page":"4863","DOI":"10.18632\/oncotarget.3120","article-title":"HDAC1,2 inhibition impairs EZH2- and BBAP- mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma","volume":"6","author":"Johnson","year":"2015","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.ejmech.2021.114049_bib18","doi-asserted-by":"crossref","first-page":"90196","DOI":"10.1172\/jci.insight.90196","article-title":"Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations","volume":"2","author":"Mondello","year":"2017","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.ejmech.2021.114049_bib19","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/imm.12136","article-title":"Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma","volume":"140","author":"Cycon","year":"2013","journal-title":"Immunology"},{"issue":"9","key":"10.1016\/j.ejmech.2021.114049_bib20","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.clml.2018.05.023","article-title":"A\u00a0phase II trial of bortezomib and vorinostat in mantle cell lymphoma and diffuse large B-cell lymphoma","volume":"18","author":"Yazbeck","year":"2018","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"issue":"9","key":"10.1016\/j.ejmech.2021.114049_bib21","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1080\/15384047.2018.1472188","article-title":"Effect of BCLAF1 on HDAC inhibitor LMK-235-mediated apoptosis of diffuse large B cell lymphoma cells and its mechanism","volume":"19","author":"Li","year":"2018","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"10.1016\/j.ejmech.2021.114049_bib22","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1038\/s41419-019-2210-0","article-title":"Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20","volume":"11","author":"Guan","year":"2020","journal-title":"Cell Death Dis."},{"issue":"14","key":"10.1016\/j.ejmech.2021.114049_bib23","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1021\/jm9900164","article-title":"Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study","volume":"42","author":"Vassiliou","year":"1999","journal-title":"J.\u00a0Med. Chem."},{"issue":"7\u20138","key":"10.1016\/j.ejmech.2021.114049_bib24","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s00018-004-4508-y","article-title":"Poly(ADP-ribosyl)ation regulation of life and death in the nervous system","volume":"62","author":"Koh","year":"2005","journal-title":"Cell. Mol. Life Sci."},{"issue":"20","key":"10.1016\/j.ejmech.2021.114049_bib25","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.1016\/j.bmcl.2007.07.091","article-title":"Rational design of conformationally restricted quinazolinone inhibitors of poly(ADP-ribose)polymerase","volume":"17","author":"Hattori","year":"2007","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"24","key":"10.1016\/j.ejmech.2021.114049_bib26","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.1021\/jm0209331","article-title":"Structure-activity relationships of 1-alkyl-5-(3, 4-dichlorophenyl)-5-[2-[(3-substituted)-1-azetidinyl]ethyl]-2-piperidones. 1. Selective antagonists of the neurokinin-2 receptor","volume":"45","author":"MacKenzie","year":"2002","journal-title":"J.\u00a0Med. Chem."},{"issue":"23","key":"10.1016\/j.ejmech.2021.114049_bib27","doi-asserted-by":"crossref","first-page":"10766","DOI":"10.1021\/jm3009376","article-title":"Property-based optimization of hydroxamate-based gamma-lactam HDAC inhibitors to improve their metabolic stability and pharmacokinetic profiles","volume":"55","author":"Choi","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2021.114049_bib28","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2141.2009.07881.x","article-title":"Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia","volume":"147","author":"Blum","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.ejmech.2021.114049_bib29","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1038\/bcj.2012.14","article-title":"The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML","volume":"2","author":"Novotny-Diermayr","year":"2012","journal-title":"Blood Cancer J."},{"issue":"19","key":"10.1016\/j.ejmech.2021.114049_bib30","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-13-0735","article-title":"First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors","volume":"19","author":"Brunetto","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.ejmech.2021.114049_bib31","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/sj.bjc.6604025","article-title":"R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies","volume":"97","author":"Arts","year":"2007","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.ejmech.2021.114049_bib32","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/1078-0432.CCR-03-0806","article-title":"Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells","volume":"10","author":"Adachi","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.ejmech.2021.114049_bib33","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1016\/j.ejmech.2008.12.008","article-title":"3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment","volume":"44","author":"Chen","year":"2009","journal-title":"Eur. J. Med. Chem."},{"issue":"9550","key":"10.1016\/j.ejmech.2021.114049_bib34","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(06)69780-8","article-title":"Acute myeloid leukaemia","volume":"368","author":"Estey","year":"2006","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ejmech.2021.114049_bib35","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1021\/acs.jmedchem.8b00136","article-title":"Class I HDAC inhibitors display different antitumor mechanism in Leukemia and prostatic cancer cells depending on their p53 status","volume":"61","author":"Li","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2021.114049_bib36","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.apsb.2020.04.002","article-title":"Design, synthesis and pharmacological evaluation of 4-(3-chloro-4-(3-cyclopropylthioureido)-2-fluorophenoxy)-7-methoxyquinoline-6-car boxamide (WXFL-152): a novel triple angiokinase inhibitor for cancer therapy","volume":"10","author":"Yao","year":"2020","journal-title":"Acta Pharm. Sin. B"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421008989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421008989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:34:00Z","timestamp":1759329240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421008989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":36,"alternative-id":["S0223523421008989"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.114049","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.114049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114049"}}